Compare
Enliven Therapeutics, Inc. vs MapLight Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc. vs Vanda Pharmaceuticals Inc.
| Latest fiscal year | Enliven Therapeutics, Inc. ELVN | MapLight Therapeutics, Inc. MPLT | Rhythm Pharmaceuticals, Inc. RYTM | Vanda Pharmaceuticals Inc. VNDA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $189.76M | $216.10M |
| Revenue growth (YoY) | n/a | n/a | +45.8% | +8.7% |
| Gross margin | n/a | n/a | 89.7% (computed) | n/a |
| Operating margin | n/a | n/a | -101.2% | -70.0% |
| Net margin | n/a | n/a | -103.6% | -102.0% |
| Net income | -$103.69M | -$161.15M | -$196.54M | -$220.47M |
| EPS (Diluted) | -$1.83 | -$18.56 | -$3.11 | -$3.74 |
| Operating cash flow | -$70.30M | -$138.14M | -$115.67M | -$109.44M |
| Free cash flow | -$70.46M | -$138.61M | -$116.63M | -$110.44M |
| Cash & equivalents | $98.90M | $46.73M | $54.30M | $84.85M |
| Total assets | $476.17M | $479.51M | $480.20M | $488.95M |
| Total liabilities | $16.57M | $21.14M | $210.17M | $161.76M |
| Shareholders' equity | $459.60M | $458.37M | $139.07M | $327.19M |
| Return on year-end equity | -22.6% | -35.2% | -141.3% | -67.4% |
| Shares outstanding | 59.44M | 44.02M | 67.21M | 59.10M |
Revenue, most recent five fiscal years
| Fiscal year | Enliven Therapeutics, Inc. | MapLight Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. | Vanda Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $189.76M Ended 2025-12-31 | $216.10M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $130.13M Ended 2024-12-31 | $198.77M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $77.43M Ended 2023-12-31 | $192.64M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $23.64M Ended 2022-12-31 | $254.38M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $3.15M Ended 2021-12-31 | $268.68M Ended 2021-12-31 |